Peptides 101: What They Are, Who They're For, and What the Evidence Actually Says

A peptide is a short chain of amino acids — the same building blocks that make up proteins. If proteins are sentences, peptides are words. They're smaller, more targeted, and they act as signaling molecules in your body, telling cells what to do.

Your body already produces thousands of peptides naturally. Insulin is a peptide. Oxytocin is a peptide. The endorphins that make you feel good after a run are peptides. They're not exotic or experimental at a basic biological level — they're fundamental to how your body operates.

What makes peptide therapy interesting is the idea of using specific synthetic peptides to enhance or modulate processes your body already runs — healing, hormone production, immune function, metabolism and more.

Three things converged. First, the science matured — researchers identified hundreds of peptides with specific biological activity, and a handful showed genuinely promising results in clinical and preclinical studies. Second, the telehealth boom made access easier — you can now consult with a peptide-prescribing physician from your couch. Third, the gray market exploded — companies selling “research peptides” directly to consumers created a massive, unregulated market that the FDA eventually cracked down on in 2023–2024.

That crackdown — the Category 2 reclassification — restricted compounding of 19 popular peptides. It also triggered the current wave of confusion, because the regulatory situation is still evolving. If you're confused about what's legal and what isn't right now, you're not alone.

Not all peptide evidence is created equal. This is the single most important thing to understand, and the thing most peptide content deliberately obscures. We use a three-tier framework:

This is complicated and changing. The short version:

In 2023–2024, the FDA placed 19 popular peptides on the Category 2 list, effectively restricting their compounding. In February 2026, HHS Secretary RFK Jr. announced approximately 14 of those would return to legal compounding status — but as of today, the formal rule change hasn't been published.

Meanwhile, GLP-1 medications like semaglutide are on a completely separate track — they're FDA-approved drugs where compounding has been restricted because the drug shortage has ended.

Do not conflate these two situations.

For current status on any compound, check our Regulatory Tracker.

If you're considering peptide therapy, the most important decision isn't which peptide — it's which provider. Look for:

• Licensed physician with peptide-specific experience
• Required lab work before prescribing
• Use of licensed compounding pharmacies (503A or 503B)
• Transparent pricing
• Willingness to discuss evidence limitations honestly

Red flags:

• No lab work required
• “Research peptide” sourcing
• Pressure to start multiple compounds immediately
• Inability to explain the evidence tier of what they’re prescribing

We built this platform because we couldn't find an independent source that met our own standards. Every compound profile includes evidence tier ratings. We cite the research behind every claim. Every provider recommendation discloses our financial relationship. We tell you when the evidence is strong and when it isn't. That's the deal.

Browse our compound profiles or check the regulatory tracker to start.